Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Ofev

- PMLiVE

Boehringer Ingelheim’s Jascayd approved by MHRA for idiopathic pulmonary fibrosis

This is the first treatment breakthrough in pulmonary fibrosis in over a decade

- PMLiVE

Oxford BioTherapeutics announces clinical milestones from its collaboration with Boehringer Ingelheim

The collaboration began in 2013 and was later expanded in 2020 and 2023

- PMLiVE

NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer

It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year

- PMLiVE

Boehringer and Immunitas agree on licensing deal for chronic inflammatory and autoimmune diseases

The agreement strengthens Boehringer Ingelheim’s growing immunology pipeline

- PMLiVE

PureTech’s deupirfenidone gets FDA and EC Orphan Drug Designations for idiopathic pulmonary fibrosis

Rare diseases are defined as conditions affecting fewer than 200,000 people in the US or fewer than five in 10,000 individuals in the European Union

- PMLiVE

Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration

There are more than three million people affected by IBD globally, with a need to improve current treatments

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m

The deal focuses on T cell-based therapies for autoimmune disease

- PMLiVE

ViiV Healthcare receives NICE recommendation for HIV prevention therapy

The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

- PMLiVE

Pfizer’s Lorviqua recommended by NICE for lung cancer

Lung cancer is the leading cause of cancer-related deaths worldwide

- PMLiVE

Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients

Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year

- PMLiVE

NICE recommends ALK’s immunotherapy to target underlying cause of hay fever

An estimated 26,800 people in England with moderate-to-severe cases could benefit from Itulazax

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links